|
Current Trends in Cellular Therapy Cancer |
| |
09:00 |  | Keynote Presentation From Ballot Box to Bedside – Advancing Stem Cell Therapies, The California Institute for Regenerative Medicine Experience
Ellen Feigal, Senior Vice President, The California Institute for Regenerative Medicine, United States of America
Advancing science into therapies for patients is a complex and expensive path to travel, and the uncertainty of success, particularly for innovative technologies, makes the funding of the translational steps towards and into the clinic, particularly challenging. This keynote will address the role the California Institute for Regenerative Medicine is playing in advancing stem cell science into the clinic, providing information on the scope of programs, initiatives, funding opportunities to help investigators from academia and companies make progress in their research. |
|
10:00 | Noninvasive Techniques for Monitoring Cell Trafficking and Enhanced Homing as part of Cellular Therapy
Joseph Frank, Senior Investigator, National Institutes of Health, United States of America
This presentation will discuss the current available translatable technologies for monitoring the migration of cells in the clinic and what are the pros and cons for using these approaches in tracking cell distribution and fate. In addition, a noninvasive method to enhance homing of stem cells to target tissues will be presented. |
10:30 | Coffee Break and Networking in the Exhibition Hall |
11:15 | Development of New Agents to Treat the Stem Cell Component of Human Prostate Cancers based on Gene Expression Profiling
Norman Maitland, Director, University of York, United Kingdom
Data on experimental approaches for the development of stem cell therapies to treat prostate cancer will be presented. Since stem cells are exquisitely programmed to resist destruction, new pre-clinical assays and agents are required. |
11:45 | Expression of Oncogenic Ras in Lgr5-positive Stem Cells Elicits Tumour Formation
Silvana Libertini, PostDoc, The Beatson Institute for Cancer Research, United Kingdom
A Brief introduction on cancer stem cells, followed by data supporting the possible role of Lgr5+ve cells as cell of origin for skin squamous cell carcinomas and other tumours. |
12:15 | Lunch Break and Networking in Exhibition Hall |
13:30 | Poster Viewing Session |
|
Commercialisation of Cellular Therapeutics |
| |
14:15 | Cancelled - Due to Family Illness
Robert Wieder, Professor of Medicine, University of Medicine & Dentistry of New Jersey, United States of America
|
14:45 | Market Trends in the use of Stem Cells for Cancer Therapeutics: From BMTs to Cord Blood
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
Select Biosciences industry coverage of the stem cells field covers many market segments. In this presentation, we focus upon the use of various classes of stem cells for hematological and solid tumor therapies. Presented here are the use of bone marrow, peripheral blood, and cord blood and the associated market trends. Also, we present the current research efforts in the hematological cancer space plus an analysis of the clinical trials pipeline. Taken together, this presentation will provide a market assessment of the utility of stem cells in cancer therapeutics. |
15:15 | Coffee Break and Networking in the Exhibition Hall |
16:00 |  | Keynote Presentation Autologous Cancer Immunotherapy in Melanoma: Cancer Stem Cells, the Case for Patient-Specific Antigen Sources
Hans Keirstead, Professor of Anatomy and Neurobiology, University of California, Irvine, United States of America
A patient’s own tumor represents an ideal source of antigens to stimulate an immune response in an immunotherapeutic approach. Recent developments in specific media formulations have enabled us to improve upon propagation speed and efficiency, making automation and scalability technically feasible. |
|
17:00 | End of Day One |
